Stay updated with breaking news from Nasdaq fate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 18,920,000 shares, an increase of 14.7% from the March 31st total of 16,490,000 shares. Based on an average daily volume of 2,780,000 shares, […] ....
Wedbush reiterated their neutral rating on shares of Fate Therapeutics (NASDAQ:FATE – Free Report) in a report issued on Tuesday, Benzinga reports. The firm currently has a $7.00 price objective on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the stock. HC Wainwright reaffirmed a neutral rating and issued a $7.00 price […] ....
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report)’s stock price traded down 5.4% during mid-day trading on Friday . The company traded as low as $4.73 and last traded at $4.77. 939,174 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 2,755,729 shares. The stock had previously closed […] ....
Needham & Company LLC restated their hold rating on shares of Fate Therapeutics (NASDAQ:FATE – Free Report) in a research report released on Thursday, Benzinga reports. A number of other equities analysts also recently issued reports on FATE. Oppenheimer reissued a market perform rating on shares of Fate Therapeutics in a report on Tuesday, February […] ....
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $6.76, but opened at $6.38. Fate Therapeutics shares last traded at $6.37, with a volume of 169,990 shares trading hands. Analysts Set New Price Targets FATE has been the topic […] ....